EyePoint Pharmaceuticals Q3 2021 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported Q3 2021 financial results, with net product revenues increasing by 49% compared to Q3 2020. The company is advancing its pipeline, with positive safety data from the Phase 1 DAVIO trial of EYP-1901 for wet AMD.
Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for wet AMD was featured at ASRS.
Topline data for DAVIO trial to be presented at AAO 2021 Annual Meeting on November 13, 2021.
Net product revenues reached $8.6 million, a 49% increase compared to $5.8 million in Q3 2020.
Jay S. Duker, M.D. was appointed as Chief Operating Officer.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
Forward Guidance
EyePoint expects cash on hand at September 30, 2021 and expected net cash inflows from product sales will enable them to fund current and planned operations through the end of 2022.